

Hiroshi Takeya

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5387476/publications.pdf>

Version: 2024-02-01

58
papers

585
citations

687363

13
h-index

713466

21
g-index

59
all docs

59
docs citations

59
times ranked

900
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical features of pulmonary cryptococcosis in non-HIV patients in Japan. <i>Journal of Infection and Chemotherapy</i> , 2015, 21, 23-30.	1.7	60
2	Efficacy of Combination Therapy with Oseltamivir Phosphate and Azithromycin for Influenza: A Multicenter, Open-Label, Randomized Study. <i>PLoS ONE</i> , 2014, 9, e91293.	2.5	46
3	In vitro and in vivo antifungal activities of T-2307, a novel arylamidine, against <i>Cryptococcus gattii</i> : an emerging fungal pathogen. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 1709-1713.	3.0	36
4	The incidence of endophthalmitis or macular involvement and the necessity of a routine ophthalmic examination in patients with candidemia. <i>PLoS ONE</i> , 2019, 14, e0216956.	2.5	30
5	Efficacy and Safety of Intravenous Peramivir Compared With Oseltamivir in High-Risk Patients Infected With Influenza A and B Viruses: A Multicenter Randomized Controlled Study. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofx129.	0.9	28
6	Two unusual cases of successful treatment of hypermucoviscous <i>Klebsiella pneumoniae</i> invasive syndrome. <i>BMC Infectious Diseases</i> , 2016, 16, 680.	2.9	21
7	Clinical Characteristics of Bacteremia Caused by Extended-spectrum Beta-lactamase-producing <i>Escherichia coli</i> ; at a Tertiary Hospital. <i>Internal Medicine</i> , 2017, 56, 1807-1815.	0.7	20
8	Clinical Features of Bacteremia Caused by Methicillin-Resistant <i>Staphylococcus aureus</i> in a Tertiary Hospital. <i>Tohoku Journal of Experimental Medicine</i> , 2011, 224, 61-67.	1.2	19
9	The intervention by an antimicrobial stewardship team can improve clinical and microbiological outcomes of resistant gram-negative bacteria. <i>Journal of Infection and Chemotherapy</i> , 2019, 25, 1001-1006.	1.7	17
10	Selection of Oral Antifungals for Initial Maintenance Therapy in Chronic Pulmonary Aspergillosis: A Longitudinal Analysis. <i>Clinical Infectious Diseases</i> , 2020, 70, 835-842.	5.8	17
11	Discovery of anti-mucoviscous activity of rifampicin and its potential as a candidate antivirulence agent against hypervirulent <i>Klebsiella pneumoniae</i> . <i>International Journal of Antimicrobial Agents</i> , 2019, 54, 167-175.	2.5	16
12	Clinical characteristics of bacteremia caused by hypermucoviscous <i>Klebsiella pneumoniae</i> at a tertiary hospital. <i>Diagnostic Microbiology and Infectious Disease</i> , 2019, 95, 84-88.	1.8	14
13	The effects of antifungal stewardship programs at a tertiary-care teaching hospital in Japan. <i>Journal of Infection and Chemotherapy</i> , 2019, 25, 458-462.	1.7	14
14	Clinical Characteristics of Rapidly Progressive Fatal Hemorrhagic Pneumonia Caused by <i>Stenotrophomonas maltophilia</i> . <i>Internal Medicine</i> , 2020, 59, 193-198.	0.7	14
15	Clinical characteristics and treatment outcomes of carbapenem-resistant Enterobacterales infections in Japan. <i>Journal of Global Antimicrobial Resistance</i> , 2022, 29, 247-252.	2.2	14
16	COVID-19-associated pulmonary aspergillosis in a Japanese man: A case report. <i>Journal of Infection and Chemotherapy</i> , 2021, 27, 911-914.	1.7	11
17	Transmission dynamics of a linear vanA-plasmid during a nosocomial multiclonal outbreak of vancomycin-resistant enterococci in a non-endemic area, Japan. <i>Scientific Reports</i> , 2021, 11, 14780.	3.3	11
18	Successful treatment with baloxavir marboxil of a patient with peramivir-resistant influenza A/H3N2 with a dual E119D/R292K substitution after allogeneic hematopoietic cell transplantation: a case report. <i>BMC Infectious Diseases</i> , 2020, 20, 478.	2.9	10

#	ARTICLE	IF	CITATIONS
19	Three Cases of Concurrent Infection with <i>Mycobacterium tuberculosis</i> and <i>Cryptococcus neoformans</i> . <i>Internal Medicine</i> , 2014, 53, 1685-1692.	0.7	9
20	Mortality caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae bacteremia; a case control study: alert to Enterobacteriaceae strains with high minimum inhibitory concentrations of piperacillin/tazobactam. <i>Diagnostic Microbiology and Infectious Disease</i> , 2019, 94, 287-292.	1.8	9
21	Nationwide surveillance of bacterial respiratory pathogens conducted by the surveillance committee of Japanese Society of Chemotherapy, the Japanese Association for Infectious Diseases, and the Japanese Society for clinical microbiology in 2014: General view of the pathogens' antibacterial susceptibility. <i>Journal of Infection and Chemotherapy</i> , 2019, 25, 657-668.	1.7	9
22	Nationwide surveillance of bacterial respiratory pathogens conducted by the surveillance committee of Japanese society of chemotherapy, the Japanese association for infectious diseases, and the Japanese society for clinical microbiology in 2016: General view of the pathogens' antibacterial susceptibility. <i>Journal of Infection and Chemotherapy</i> , 2020, 26, 873-881.	1.7	9
23	Concurrent Subcutaneous Candidal Abscesses and Pulmonary Cryptococcosis in a Patient with Diabetes Mellitus and a History of Corticosteroid Therapy. <i>Internal Medicine</i> , 2014, 53, 1385-1390.	0.7	8
24	Effectiveness of weekly polymerase chain reaction-based open reading frame typing analysis of all newly isolated methicillin-resistant <i>Staphylococcus aureus</i> strains for controlling nosocomial infections. <i>Journal of Infection and Chemotherapy</i> , 2016, 22, 733-737.	1.7	8
25	Complete Genome Sequence of <i>Acinetobacter baumannii</i> ATCC 19606 ^T , a Model Strain of Pathogenic Bacteria Causing Nosocomial Infection. <i>Microbiology Resource Announcements</i> , 2020, 9, .	0.6	8
26	Siderophore production as a biomarker for <i>Klebsiella pneumoniae</i> strains that cause sepsis: A pilot study. <i>Journal of the Formosan Medical Association</i> , 2022, 121, 848-855.	1.7	8
27	Discrepant Antigen-specific Antibody Responses Causing SARS-CoV-2 Persistence in a Patient Receiving B-cell-targeted Therapy with Rituximab. <i>Internal Medicine</i> , 2021, 60, 3827-3831.	0.7	8
28	Clinical and virulence factors related to the 30-day mortality of <i>Klebsiella pneumoniae</i> bacteremia at a tertiary hospital: a case-control study. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2019, 38, 2291-2297.	2.9	7
29	Incidental finding of neurosyphilis with intracranial hemorrhage and cerebral infarction: A case report. <i>Journal of Infection and Chemotherapy</i> , 2021, 27, 521-525.	1.7	7
30	The Comparison of the Efficacy of Baloxavir and Neuraminidase Inhibitors for Patients with Influenza A in Clinical Practice. <i>Internal Medicine</i> , 2020, 59, 1509-1513.	0.7	7
31	A mouse model of rapidly progressive fatal haemorrhagic pneumonia caused by <i>Stenotrophomonas maltophilia</i> . <i>Journal of Global Antimicrobial Resistance</i> , 2020, 23, 450-455.	2.2	6
32	Disseminated <i>Mycobacterium abscessus</i> subsp. <i>massiliense</i> infection in a Good's syndrome patient negative for human immunodeficiency virus and anti-interferon- γ autoantibody: a case report. <i>BMC Infectious Diseases</i> , 2020, 20, 431.	2.9	6
33	Physical health complaints among healthcare workers engaged in the care of critically ill COVID-19 patients: A single tertiary-care center prospective study from Japan. <i>Journal of Infection and Public Health</i> , 2021, 14, 1263-1267.	4.1	6
34	<i>Corynebacterium jeikeium</i> -induced infective endocarditis and perivalvular abscess diagnosed by 16S ribosomal RNA sequence analysis: A case report. <i>Journal of Infection and Chemotherapy</i> , 2021, 27, 906-910.	1.7	5
35	Empirical antibiotic usage and bacterial superinfections in patients with COVID-19 in Japan: A nationwide survey by the Japanese Respiratory Society. <i>Respiratory Investigation</i> , 2021, 60, 154-154.	1.8	5
36	Isoniazid-induced Immune Thrombocytopenia. <i>Internal Medicine</i> , 2021, 60, 3639-3643.	0.7	4

#	ARTICLE	IF	CITATIONS
37	A Case of Imported <i>Taenia asiatica</i> Infection in Japan. Japanese Journal of Infectious Diseases, 2018, 71, 170-171.	1.2	3
38	Daily practice and prognostic factors for pneumonia caused by methicillin-resistant <i>Staphylococcus aureus</i> in Japan: A multicenter prospective observational cohort study. Journal of Infection and Chemotherapy, 2020, 26, 242-251.	1.7	3
39	Blood culture reports by infectious disease physicians can improve prognosis of bacteremia, including weekend-onset cases. International Journal of Infectious Diseases, 2020, 100, 174-179.	3.3	3
40	A Case of Muscle Biopsy-proven Drug-induced Microscopic Polyangiitis in a Patient with Tuberculosis. Internal Medicine, 2022, , .	0.7	3
41	Clinical Characteristics and Low Susceptibility to Daptomycin in <i>Enterococcus faecium</i> Bacteremia. Tohoku Journal of Experimental Medicine, 2017, 243, 211-218.	1.2	2
42	Clinical usefulness of very high serum soluble interleukin-2 receptor levels for the detection of tuberculous peritonitis in a patient with chronic myelogenous leukemia. Journal of Infection and Chemotherapy, 2020, 26, 1054-1057.	1.7	2
43	Three-year epidemiological analysis of <i>Clostridioides difficile</i> infection and the value of hospital-infection control measures in a tertiary-care teaching hospital in Japan using PCR-based open-reading frame typing. Journal of Infection and Chemotherapy, 2021, 27, 179-184.	1.7	2
44	Invasive pulmonary aspergillosis caused by <i>Aspergillus terreus</i> diagnosed using virtual bronchoscopic navigation and endobronchial ultrasonography with guide sheath and successfully treated with liposomal amphotericin B. Infection, 2021, 49, 1049-1054.	4.7	2
45	Modified Pitt bacteremia score for predicting mortality in patients with candidaemia: A multicentre seven-year retrospective study conducted in Japan. Mycoses, 2021, 64, 1498-1507.	4.0	2
46	The effect of intervention by an antimicrobial stewardship team on anaerobic bacteremia. Anaerobe, 2020, 64, 102214.	2.1	2
47	Impact of coronavirus disease 2019 on infectious disease treatment and infection control at a tertiary hospital in Japan. Journal of Infection and Chemotherapy, 2022, , .	1.7	2
48	Risk factor analysis for piperacillin-tazobactam-resistant <i>Enterobacter</i> spp. bacteremia at a tertiary hospital. Diagnostic Microbiology and Infectious Disease, 2021, 100, 115342.	1.8	1
49	Complete Genome Sequence of a Clinical Isolate of <i>Acinetobacter baumannii</i> Harboring 11 Plasmids. Microbiology Resource Announcements, 2021, 10, e0069521.	0.6	1
50	Risk factors for acute kidney injury in vancomycin and piperacillin/tazobactam combination therapy: A retrospective study. Journal of Infection and Chemotherapy, 2021, 27, 1614-1620.	1.7	1
51	Efficacy and Safety of Vancomycin in Treatment based on the TDM Guideline for Antibiotics 2016. Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences), 2019, 45, 576-583.	0.1	1
52	Complete Genome Sequence of <i>Acinetobacter pittii</i> OCU_Ac17, Isolated from Human Venous Blood. Microbiology Resource Announcements, 2021, 10, e0069621.	0.6	0
53	Congenital bronchial atresia complicated by a lung abscess due to <i>Aspergillus fumigatus</i> : a case report. BMC Pulmonary Medicine, 2021, 21, 2.	2.0	0
54	Effectiveness of Antibacterial Prophylaxis with Non-Absorbable Polymyxin B Compared to Levofloxacin after Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2014, 124, 1145-1145.	1.4	0

#	ARTICLE	IF	CITATIONS
55	Investigation of Linezolid Administration to Pediatric Patients with Febrile Neutropenia. Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences), 2015, 41, 894-899.	0.1	0
56	Management of Pulmonary Mycoses. The Journal of the Japanese Society of Internal Medicine, 2020, 109, 293-300.	0.0	0
57	Simulation of the Dosing Regimen of the Anti-MRSA Drug Daptomycin in a Patient Receiving Thrice-weekly Hemodialysis: Is It Reasonable to Administer 1.5 Times Dosage before the 72-hour Interval after Dialysis?. Japanese Journal of Clinical Pharmacology and Therapeutics, 2020, 51, 325-330.	0.1	0
58	Body Mass Index of Elderly Patients with Normal Renal Function as a Determining Factor for Initial Vancomycin Regimen Designing. Chemotherapy, 2022, 67, 193-200.	1.6	0